A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors. This is an ASCO Meeting Abstract from the 2011 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results